Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Ipilimumab/nivolumab

Grade 1 dermatitis and facial palsy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mezni E, et al. Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management. [Review] Frontiers in Immunology 15: 1375497, Jan 2024. Available from: URL: https://dx.doi.org/10.3389/fimmu.2024.1375497 Mezni E, et al. Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management. [Review] Frontiers in Immunology 15: 1375497, Jan 2024. Available from: URL: https://​dx.​doi.​org/​10.​3389/​fimmu.​2024.​1375497
Metadaten
Titel
Ipilimumab/nivolumab
Grade 1 dermatitis and facial palsy
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58235-8

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Sodium-chloride

Case report

Anakinra